Tacalyx is a privately held biotech company focused on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer.

Tacalyx is a pioneer in the development of novel antibody-based therapeutics targeting TACAs. They are developing a pipeline of therapies against multiple solid tumour indications with high unmet need.

TACAs are formed during malignant transformation in a microevolutionary process. The expression of TACAs is elevated in many cancer cell types which makes them attractive potential targets for cancer treatment by harnessing and directing the natural immune response.